These innovative agents represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://arunbexk521956.blog2news.com/39678012/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide